Psilocybin has gained momentum in recent years, and reform efforts are making significant progress across the United States. Reforms in Arizona, Connecticut, and Washington are notable examples of this positive change — from providing access to psychedelic-assisted treatments to decriminalizing possession.
In Arizona, lawmakers recently introduced legislation allowing certain patients access to psychedelic-assisted treatment using substances like MDMA and psilocybin. Similarly, legislators in Connecticut voted for an act that decriminalizes the possession of small amounts of psilocybin. And most recently, Washington’s governor signed a bill promoting research into psilocybin while creating a pilot program to provide therapeutic access.
The progress in these three states is paving the way for much-needed reform and greater access to psychedelic therapies. With research and further discussion, it’s expected that more comprehensive legalization of psilocybin may come soon.
Arizona Psilocybin Reform
Arizona is making progress toward psychedelic reform. The state Senate has recently approved budget legislation that includes provisions to fund research into the medical potential of psilocybin mushrooms for various conditions.
This funding is meant to be used for clinical trials capable of being approved by the federal Food and Drug Administration (FDA) for the treatment of any of 13 listed conditions, including post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms, and substance misuse disorder.
The bill also outlines an advisory council responsible for overseeing applications and providing recommendations on psychedelic-assisted therapy based on current federal and state research policy. The council must include representatives from relevant organizations, such as law enforcement officials, military veterans, and physicians. Additionally, people who receive the grant money and work on the clinical trials will be protected from prosecution under this bill.
As the debate over psychedelic reform continues, Connecticut is also becoming a leader in taking progressive action to address the issue. The state House of Representatives has approved a bill decriminalizing possessing psilocybin mushrooms for personal use.
This is an important step towards recognizing the potential medical benefits of psychedelics and reducing criminal penalties associated with possessing small amounts of the substance. The legislation will now move on to the Senate for consideration before potentially being sent to Governor Ned Lamont’s desk for final approval.
The bill is just one part of Connecticut’s ongoing effort to explore ways to use psychedelic-assisted therapy and treatments available safely and responsibly. In addition to HB 6734, Gov. Lamont signed a large-scale budget bill last year that provides certain patients access to psychedelic-assisted therapy using MDMA and psilocybin.
Separate legislation has also been introduced to provide state funds to the Department of Mental Health and Addiction Services for the current fiscal year to establish a “psychedelic-assisted therapy pilot program.”
These efforts have come at a time when more states are taking steps towards recognizing the potential medical benefits of psychedelics and decriminalizing possession of small amounts for personal use.
Connecticut is showing its commitment to progressive reform on this issue and providing an example for other states in the U.S. looking to move forward on this important topic. With HB 6734 now moving to the Senate, Connecticut will likely be taking a big step toward reforming its approach to psychedelics.
Washington has made significant progress in reforming its laws around psilocybin. Governor Jay Inslee signed into law a bill that promotes psilocybin research and creates a pilot program to provide therapeutic access to the psychedelic for mental health treatment.
The bill was introduced earlier this session but had been significantly watered down from its original scope. A later amendment by Rep. Nicole Macri was added to the pilot program, allowing the University of Washington (UW) to provide access to psychedelics for military veterans and first responders in treating post-traumatic stress disorder (PTSD) and mood and substance use disorders.
In addition, Governor Inslee partially vetoed sections of the legislation creating a Psilocybin Advisory Board and an Interagency Psilocybin Work Group. The workgroup would have been charged with tasks such as developing a comprehensive regulatory framework for a regulated psilocybin system and reviewing research into the psychedelic.
Despite these vetoed sections, Washington has made significant progress toward recognizing the potential of psychedelics in mental health treatment and further research into the area. Advocates remain hopeful that more comprehensive changes will be forthcoming in the future.
Washington is just one of several states to move forward on psychedelic reform; Arizona, Connecticut, and Oregon are among those making similar progress. With a growing acceptance of psychedelics as a viable solution for treating certain mental health issues, there is hope that more states will join this trend in reforming their regulations to allow for more research and access.
Enjoyed that first hit? Come chill with us every week at the Friday Sesh for a freshly packed bowl of the week’s best cannabis news!